Replies to post #26631 on iBio Inc (IBIO)

[redspeed]

$1/pps could be conservative for whats in their pipe...

I guess it depends on what pipe your using?

When I use the IBIO pipeline, I see nothing for humas that even completed an IND study.

Absolutely nothing.

For those that don't know what and IND is...

The purpose of IND-enabling studies is to secure approval to conduct the first-in-human clinical trials with a new drug. An IND application contains information on pharmacology and toxicology, manufacturing (e.g., composition, production, stability, etc.), human clinical study protocols, and investigator information.

Oh and there is absolutely nothing in Phase I

absolutely nothing in Phase II

absolutely nothing in Phase III

IBIO has 9 assets in "discovery".

Basically we have an idea and we are playing around with it. We could be playing around with it for years as we don't know what we don't know.

Those that knows BIOs know it will take $100's of millions to push these assets through the pipeline and that is the elephant in the room. Where is this money going to come from? If you said dilution you are right. I guess you could hope for $100's of millions of grant money like every other Biotech.

If you get a chance, please ask the JMP Securities - a no-nonsense securities analyst about $100's of millions and please report back. It looks like he's actually a real analyst and not a fake Biotech analyst giving financial advice.

TIA

[redspeed]

With the dead hamsters, there is a little less in their pipeline today. Wonder why they waited until now to tell investors IBIO 202 a stone cold failure and IBIO 101 light years away from ever getting into the clinic.

JMP Securities - maybe another self serving stock promoter aware the company on a fast train to nowheresville and he wanted out at .30 something cents

JMP Securities - a no-nonsense securities rating & analysis firm

$1/pps could be conservative for whats in their pipe....

What is clear is shareholders are very upset. I suspect they will take action.